Recevez les dernières nouvelles sur l'action KalVista Pharmaceuticals avec des mises à jour sur les tendances du marché, les données financières et les analyses de Benzinga. Restez informé des performances de KALV

Dernières nouvelles pour

KALVISTA PHARMACEUTICALS INC

KalVista Pharmaceuticals

KalVista Pharma

KalVista Pharmaceuticals Inc is a pharmaceutical company developing and delivering oral therapies for individuals affected by rare diseases with unmet needs. The company applies its knowledge in the kallikrein-kinin system (KKS) and oral drug discovery to develop small-molecule protease inhibitor medicines to address the needs of patients with diseases driven by plasma kallikrein and Factor XIIa. Its FDA-approved product EKTERLY (sebetralstat) is a novel, orally delivered, small-molecule plasma kallikrein inhibitor for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged twelve years and older.

KalVista Pharmaceuticals, Inc. - Common Stock

KalVista Pharmaceuticals Inc

Press Releases

KalVista Pharmaceuticals to Provide Operational Update and Fiscal Quarter Financial Results on September 11, 2025

KalVista Pharmaceuticals Provides Operational Update and Reports Fiscal Quarter Financial Results

KalVista Pharmaceuticals Announces European Commission and Swissmedic Approval of EKTERLY® (sebetralstat), First and Only Oral On-Demand Treatment for Hereditary Angioedema

KalVista Pharmaceuticals Announces Proposed Offering of $110.0 Million of Convertible Senior Notes

KalVista Prices Upsized Offering of $125.0 Million of 3.250% Convertible Senior Notes Due 2031

Small Cap

KalVista Pharmaceuticals to Present New EKTERLY® (sebetralstat) Data at the 20th German Allergy Congress

KalVista Pharmaceuticals Announces Appointment of Bethany L. Sensenig to Board of Directors

KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

KalVista Pharmaceuticals Appoints Bilal Arif as Chief Operating Officer and Linea Aspesi as Chief People Officer

KalVista Pharmaceuticals Presents New Data Highlighting the Potential of EKTERLY® (sebetralstat) to Transform On-Demand Hereditary Angioedema Treatment in Europe

KALV

Arcturus Therapeutics Holdings Inc. - Common Stock

Arcturus Therapeutics

Bicycle Therapeutics plc - American Depositary Shares

Bicycle Therapeutics

Cullinan Therapeutics, Inc. - Common Stock

Cullinan Therapeutics

COMPASS Pathways Plc - American Depository Shares

Compass Pathways

Compass Therapeutics, Inc. - Common Stock

Compass Therapeutics

Corvus Pharmaceuticals, Inc. - Common Stock

Corvus Pharma

CytomX Therapeutics

Emergent BioSolutions

Monte Rosa Therapeutics, Inc. - Common Stock

Monte Rosa Therapeutics

Gossamer Bio

Inhibrx Biosciences

Lexicon Pharmaceuticals, Inc. - Common Stock

Lexicon Pharmaceuticals

MeiraGTx Hldgs

MoonLake Immunotherapeutics - Class A Ordinary Shares

MoonLake

Monopar Therapeutics

Neurogene

Ocugen

Olema Pharmaceuticals, Inc. - Common Stock

Olema Pharmaceuticals

Organogenesis Holdings

Prothena Corporation plc - Ordinary Shares

Prothena Corp

Regenxbio

Rigel Pharmaceuticals, Inc. - Common Stock

Comments

KalVista Pharmaceuticals Actualités boursières

Actualités

Dernières nouvelles pour

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL